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Early diagnosis and treatment of the respiratory and gastrointestinal complications of cystic fibrosis (CF) have led to improved survival with
many patients living beyond the fourth decade. Along with this increased life expectancy is the risk of further disease associated with the chronic
manifestations of their condition. We report a patient with documented CF related liver disease for which he was under routine surveillance that
presented with histologically proven hepatocellular carcinoma (HCC). It is important that physicians are aware of this association as increased
vigilance may lead to earlier diagnosis and perhaps, a better outcome.
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Improved understanding of cystic fibrosis (CF) and advances
in treatment have led to increased patient life expectancy over the
past two decades. Cystic fibrosis is themost common life-limiting
autosomal recessive disease among people of European descent
and is no longer an illness only affecting childhood. Current
average life expectancy is over 30 years and it is anticipated that,
with improvements in nutrition and disease modification, life
expectancy will extend to more than 40 years [1]. This im-
provement in longevity is due to advances in management of
disease complications and new therapies, which are altering the
natural history of the disease. Unfortunately, improved survival
has been associated with new manifestations of chronic disease;
the odds ratio is 20:1 for developing a gastrointestinal malignancy
in cystic fibrosis patients between the ages of 20 and 29 years of
age [2]. Two case reports in the literature, one of which was in our⁎ Corresponding author. Department of Interventional Radiology, Guys and
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cystic fibrosis related liver disease and hepatocellular carcinoma
(HCC) [3,4]. We present a further case occurring in a patient with
previously documented cirrhosis.
2. Case
A 34-year-old man, diagnosed with cystic fibrosis at 4 years
of age, was under routine surveillance for documented severe
cirrhosis and portal hypertension, which had required gastro-
oesophageal variceal, banding 15 years previously. His clinical
course and biochemical markers had remained stable over the
previous 5 years; bilirubin 21(1–21 µmol/L), alkaline phos-
phatase 218 U/L (35–129 U/L), gamma glutamyl transferase
155 U/L (5–36 U/L), alanine aminotransferase 43(4–50 U/L),
albumin 23(30–90 g/L). His international normalised ratio
(INR) was 1.29, erythrocyte sedimentation rate (ESR) 22(0–25)
and C-reactive protein was 14(0–4). Haematological laboratory
investigations revealed a thrombocytopenia with platelets of 36
(150–400×109), which was secondary to his splenomegaly. All
other laboratory investigations were normal. Respiratory
function had also remained stable over the previous years;d by Elsevier B.V. All rights reserved.
Fig. 1. a) Post gadolinium enhanced T1weighted images through the liver show a hypervascular area on the arterial phase image. b) Axial MRI image following
administration of the paramagnetic contrast agent SPIO shows a focal area of decreased uptake in a large central area in the liver. The liver has a macronodular cirrhotic
pattern with focal confluent fibrosis. Note the presence of splenomegaly with multiple siderotic nodules.
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room air with infrequent hospital admissions for infective
exacerbations. A routine 6 monthly liver ultrasound revealed two
new hypo echoic lesions in segment 4 of a small nodular liver
which had a diffusely heterogeneous echo texture. He was also
noted to have portal vein thrombosis. Contrast enhanced liver
ultrasound and triphasic computed tomography (64 slice MDCT,Fig. 2. H&E, 200×. A higher power image showing tumour cells, arrangedSiemens Erlanger, Germany) revealed a more extensive mass
lesion that measured 7 cm, with early arterial phase contrast
hyper-enhancement followed by contrast washout in the later
phases. Since there was a high suspicion of hepatocellular
carcinoma, a double contrast MRI liver was performed showing
typical appearances of hepatocellular carcinoma: arterial phase
contrast hyper-enhancement (Fig. 1) and lack of uptake of superin trabeculae of three or more cells in thickness, with bile production.
290 D.H. O'Donnell et al. / Journal of Cystic Fibrosis 8 (2009) 288–290paramagnetic iron oxide (SPIO) negative contrast agent. (Fig. 1b).
The imaging also confirmed that this was a single lesion.
Ultrasound guided core biopsy was then performed which
confirmed the diagnosis of hepatocellular carcinoma (Fig. 2). In
consultation with the hepatobiliary surgical unit, it was decided
that the size of the tumour and presence of severe liver disease
precluded any form of surgical resection. He was commenced on
the tyrosine kinase inhibitor Sorafenib. Interestingly his alpha-
fetoprotein levels were within normal parameters 3.7(0–5.8),
however CA19-9 was elevated at 162.3 (0–37). He remains well
at follow-up, 21months after the diagnosis of HCCwith a follow-
up CT showing a marginal increase in tumour size however no
evidence of metastatic disease.
3. Discussion
The clinical manifestations of liver disease in cystic fibrosis
(CF) may occur at any age. However, the likelihood of liver
disease in an individual patient increases with age until
adolescence [5]. Up to 40% of patients with CF develop liver
disease but only 1–2% progress to end-stage liver disease [6–8].
Although the presence of macro nodular cirrhosis makes the
diagnosis of HCC by ultrasound difficult, ultrasound remains the
first line investigation as recommended by the European
Association for the Study of the Liver (EASL) and the American
Association for the Study of Liver Diseases (AASLD) [6–8].
The performance of ultrasound (US) as a screening tool varies
widely depending on the experience of the examiner and the
technology used. Recent studies generally indicate a 60%
sensitivity and specificity greater than 90% with a positive
predictive value of 70% for diagnosis HCC on ultrasound [9].
It is becoming clear that all patients with CF-related liver
disease should have bi-annual liver US in specialist centres
where comparison with previous images is mandatory to assess
for any interval change. Ultrasound is easy to perform, is cost
effective and provides a rapid assessment of the liver but it is
subjective and depends on the experience of the user. The
hepatic sonographic appearances include patchy or diffuse
hyper-echogenicity reflecting fatty infiltration, coarse or irre-
gular parenchyma changes, nodularity and thickened hyper-
echoic periportal tissues representing periportal fibrosis [9,10].
These changes are thought to be due to thickened inspissated bile
secretions causing biliary obstruction and cirrhosis. Biliary duct
and gallbladder calculi and appearances of portal hypertension
(including portal venous flow and calibre abnormalities),
splenomegaly and varices are common extra hepatic manifesta-
tions. Several scoring systems have been recommended,
however no consensus agreement has been reached on the
optimum grading and scoring systems have been found in at
least one report to have wide intra-observer variability [10].
Recent EASL and AASLD guidelines also include contrast-
enhanced US in primary investigation of cirrhotic livers and
several reports attest to the ability of contrast-enhanced US todiagnose HCC with an accuracy that approaches that of
optimized multidetector computed tomography (MDCT) or
dynamic magnetic resonance (MRI) [11]. Double contrast MRI
is becoming the most common second line examination of
choice in patients with cirrhosis as it is reliable and reproducible
with a high negative predictive value [12,13] with the advantage
of no ionising radiation and a large field of view which can
assess the entire liver in arterial phases of enhancement, a
limitation of conventional and contrast-enhanced US. Most
centres recommend that biannual blood alpha-fetoprotein (AFP)
levels should also be obtained at the time of US assessment;
although they were within normal limits in our patient they may
indicate early HCC even in the absence of the typical imaging
appearances.
In our patient the HCC lesion was advanced at diagnosis
precluding curative treatment and suggesting that this tumour
had an aggressive growth pattern as the patient had been
routinely followed with bi-annual ultrasound. As more patients
with cystic fibrosis survive into adulthood, we recommend
increased awareness and vigilance of this increasingly prevalent
complication with early referral for further imaging.References
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